Literature DB >> 7376658

Paroxysmal nocturnal hemoglobinuria--present status and future prospects.

W F Rosse.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7376658      PMCID: PMC1272021     

Source DB:  PubMed          Journal:  West J Med        ISSN: 0093-0415


× No keyword cloud information.
  31 in total

1.  Paroxysmal nocturnal haemoglobinuria.

Authors:  J V DACIE
Journal:  Proc R Soc Med       Date:  1963-07

2.  Reclassification of the thrombocytopenias by the Cr51-labeling method for measuring platelet life span.

Authors:  P COHEN; F H GARDNER; G O BARNETT
Journal:  N Engl J Med       Date:  1961-06-22       Impact factor: 91.245

3.  STUDIES ON DESTRUCTION OF RED BLOOD CELLS. II. CHRONIC HEMOLYTIC ANEMIA WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: CERTAIN IMMUNOLOGICAL ASPECTS OF THE HEMOLYTIC MECHANISM WITH SPECIAL REFERENCE TO SERUM COMPLEMENT.

Authors:  T H Ham; J H Dingle
Journal:  J Clin Invest       Date:  1939-11       Impact factor: 14.808

4.  Paroxysmal nocturnal hemoglobinuria terminating in acute myeloblastic leukemia.

Authors:  D E Jenkins; R C Hartmann
Journal:  Blood       Date:  1969-02       Impact factor: 22.113

5.  Mechanisms of immune lysis of the red cells in hereditary erythroblastic multinuclearity with a positive acidified serum test and paroxysmal nocturnal hemoglobinuria.

Authors:  W F Rosse; G L Logue; J Adams; J H Crookston
Journal:  J Clin Invest       Date:  1974-01       Impact factor: 14.808

6.  A platelet and granulocyte membrane defect in paroxysmal nocturnal hemoglobinuria: usefulness for the detection of platelet antibodies.

Authors:  R H Aster; S E Enright
Journal:  J Clin Invest       Date:  1969-07       Impact factor: 14.808

7.  Differences in the terminal steps of complement lysis of normal and paroxysmal nocturnal hemoglobinuria red cells.

Authors:  T A Rouault; W F Rosse; S Bell; J Shelburne
Journal:  Blood       Date:  1978-02       Impact factor: 22.113

8.  Immune lysis of normal human and paroxysmal nocturnal hemoglobinuria (PNH) red blood cells. I. The sensitivity of PNH red cells to lysis by complement and specific antibody.

Authors:  W F Rosse; J V Dacie
Journal:  J Clin Invest       Date:  1966-05       Impact factor: 14.808

9.  The aplastic anaemia--paroxysmal nocturnal haemoglobinuria syndrome.

Authors:  S M Lewis; J V Dacie
Journal:  Br J Haematol       Date:  1967-03       Impact factor: 6.998

10.  Aplastic anemia treated by allogeneic bone marrow transplantation: a report on 49 new cases from Seattle.

Authors:  R Storb; E D Thomas; P L Weiden; C D Buckner; R A Clift; A Fefer; L P Fernando; E R Giblett; B W Goodell; F L Johnson; K G Lerner; P E Neiman; J E Sanders
Journal:  Blood       Date:  1976-12       Impact factor: 22.113

View more
  5 in total

1.  Retrovirus-induced feline pure red cell aplasia. Hematopoietic progenitors are infected with feline leukemia virus and erythroid burst-forming cells are uniquely sensitive to heterologous complement.

Authors:  J L Abkowitz; R D Holly; C K Grant
Journal:  J Clin Invest       Date:  1987-10       Impact factor: 14.808

Review 2.  Diagnosis and management of paroxysmal nocturnal hemoglobinuria.

Authors:  Charles Parker; Mitsuhiro Omine; Stephen Richards; Jun-Ichi Nishimura; Monica Bessler; Russell Ware; Peter Hillmen; Lucio Luzzatto; Neal Young; Taroh Kinoshita; Wendell Rosse; Gerard Socié
Journal:  Blood       Date:  2005-07-28       Impact factor: 22.113

Review 3.  Management issues in paroxysmal nocturnal hemoglobinuria.

Authors:  Gabrielle Meyers; Charles J Parker
Journal:  Int J Hematol       Date:  2003-02       Impact factor: 2.490

4.  Enhanced complement-mediated lysis of type III paroxysmal nocturnal hemoglobinuria erythrocytes involves increased C9 binding and polymerization.

Authors:  V W Hu; A Nicholson-Weller
Journal:  Proc Natl Acad Sci U S A       Date:  1985-08       Impact factor: 11.205

5.  Decay-accelerating factor is present on paroxysmal nocturnal hemoglobinuria erythroid progenitors and lost during erythropoiesis in vitro.

Authors:  J G Moore; M M Frank; H J Müller-Eberhard; N S Young
Journal:  J Exp Med       Date:  1985-10-01       Impact factor: 14.307

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.